Close Menu

Chip-Making, Harvard-Style

Premium

By John F. Lauerman

In 1997, Harvard toxicologist Leona Samson sent a postdoc to Santa Clara to participate in an Affymetrix user program. She thought the experience could help her lab get “ahead of the game” in its studies of yeast’s response to DNA damage. She was right: Early last year, Samson dropped a bombshell in her field when her data showed that expression levels in about one-third of the S. cerevisiae genome change significantly after damage from alkylating agents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.